Federal scientists must now disclose royalties from government inventions

What it does

This bill requires federal executive branch employees and members of certain science and health advisory committees to disclose royalties they receive from inventions developed during their government work. It mandates that agencies publish these royalty disclosures on their websites, report waivers of conflict-of-interest rules to Congress, and review whether contractors receiving government money have undisclosed royalty conflicts. The bill aims to increase transparency about potential financial conflicts of interest among federal officials and advisors.

Why we flagged it

The bill's core mechanism is mandatory disclosure of royalty income by federal employees and advisory committee members, coupled with congressional notification of ethics waivers and conflict-of-interest reviews for contractors. This is fundamentally an ethics and transparency measure, not a substantive policy change.

What the text implies

• The bill expands the definition of 'covered individuals' to include members of 10+ named advisory committees plus any other advisory committee the GAO determines meets criteria, creating an open-ended class of filers. This could significantly increase the number of people required to disclose royalties.
• Public disclosure of royalty amounts and sources for certain federal employees may create reputational or professional consequences for scientists and researchers, potentially affecting recruitment to government advisory roles.
• The 5-year sunset on expanded advisory committee coverage means the transparency regime will contract unless Congress affirmatively reauthorizes it, creating a compliance cliff.
• Agencies must now review contractor royalty payments as part of conflict-of-interest screening, but the bill does not specify what action agencies must take if conflicts are identified—only that they report findings to Congress.
• The bill overrides confidentiality protections in the Stevenson-Wydler Technology Innovation Act and 35 U.S.C. § 209 for royalty disclosures, potentially exposing sensitive information about government-developed technologies and licensing arrangements.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens public accountability by requiring disclosure of financial conflicts of interest among federal employees and advisors who influence public health and science policy. Citizens gain visibility into potential conflicts that could bias government decision-making, and Congress gains tools to oversee ethics compliance. The transparency mechanism does not restrict citizens' rights or impose new costs on the public.

Named in the bill

Office of Government Ethics, Government Accountability Office, Federal Acquisition Regulatory Council, Office of Management and Budget, National Science Advisory Board for Biosecurity, Advisory Committee on Immunization Practices, Advisory Commission on Childhood Vaccines, National Vaccine Advisory Committee, Vaccines and Related Biological Products Advisory Committee, Defense Science Board, Board of Scientific Advisors of the National Cancer Institute, Homeland Security Science and Technology Advisory Committee — and 7 more

Where it stands

1 cosponsor: 1 Republicans.

• Mar 5, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 5, 2025 — Referred to Senate Committee on Homeland Security and Governmental Affairs · Congress.gov: “Read twice and referred to the Committee on Homeland Security and Governmental Affairs”
• Jul 30, 2025 — Reported out of committee · Congress.gov: “Committee on Homeland Security and Governmental Affairs. Ordered to be reported without amendment favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,529,833 in lobbying spend. A filing names 26 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Rand Paul, the sponsor, reported $94,645 in PAC receipts in the 2026 cycle.

• Association of American Medical Colleges — $1,529,833 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.